Obesity Drug Stocks: Time to Buy Manufacturers of Ozempic, Mounjaro, Others?
The demand for drug therapies for obesity is on the rise. New drugs with efficacy rivaling bariatric surgery, with only minor tolerability issues, have replaced older drugs burdened with significant cardiovascular side effects and mediocre efficacy. The approval of Novo Nordisks’ NVO GLP-1 agonist Wegovy in 2021 led to increased demand for the active ingredient … Read more